The Upstream and Downstream products of (4-CHLORO-2-METHYLSULFANYL-PYRIMIDIN-5-YL)-METHANOL

4-Chloro-2-methylsulfanyl-pyrimidine-5-yl)-methanol, commonly referred to as CU-103, is a research compound that has been studied for its potential therapeutic effects on certain types of cancer.
In the chemical industry, CU-103 is considered to be an upstream product, as it is a raw material used in the production of downstream products.

The Upstream Products

Upstream products are the raw materials or starting materials required for the production of downstream products.
In the case of CU-103, the upstream products include the raw materials required for its synthesis, such as chlorine, methanol, and 2-methylsulfanyl-pyrimidine-5-carbaldehyde.
These raw materials are themselves manufactured through a series of chemical reactions using other upstream products, such as hydrogen chloride and methylene alcohol.

The Downstream Products

Downstream products, also known as finished products, are the end products of a chemical process that have undergone some form of manufacturing or processing.
For CU-103, the downstream products are the final products that are used for therapeutic purposes.

One of the downstream products of CU-103 is a drug called BC814, which is being developed by the pharmaceutical company BeiGene for the treatment of cancer.
BC814 is a small molecule inhibitor of the bromodomain and extraterminal domain (BET) protein family, which is involved in regulating gene expression and cell growth.
By inhibiting the BET protein family, BC814 can suppress the growth and survival of cancer cells.

Another downstream product of CU-103 is HMS7007, which is also being developed by BeiGene for the treatment of cancer.
HMS7007 is a B-cell maturation antagonist that targets the Bruton's tyrosine kinase (BTK) protein, which is involved in the development and survival of B-cell malignancies.
By blocking the BTK protein, HMS7007 can inhibit the growth and proliferation of cancer cells.

The Synthesis of CU-103

The synthesis of CU-103 involves a series of chemical reactions that convert the raw materials into the final product.
The synthesis process typically involves several stages, including:

1. Halogenation: In this stage, chlorine gas is added to methanol to form chloromethane.
   
2. Nucleophilic Substitution: In this stage, 2-methylsulfanyl-pyrimidine-5-carbaldehyde is treated with sodium hydroxide to form 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxaldehyde.
   
3. Reductive Amination: In this stage, 4-chloro-2-methylsulfanyl-pyrimidine-5-carboxaldehyde is treated with ammonia to form 4-chloro-2-methylsulfanyl-pyrimidine-5-amine.
   
4. Hydrogenation: In this stage, 4-chloro-2-methylsulfanyl-pyrimidine-5-amine is treated with hydrogen gas to form 4-chloro-2-methylsulfanyl-pyrimidine-5-methanol.
   

The Purification of CU-103

After the synthesis process is complete, CU-103 must be purified to remove any impurities that may have been introduced during the synthesis process.
This purification process